Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $18.00 Average PT from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.00.

A number of analysts have weighed in on ENTA shares. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. JMP Securities raised their price target on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a "market outperform" rating in a research report on Tuesday, June 3rd.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 5.3% during the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company's stock valued at $720,000 after purchasing an additional 6,549 shares in the last quarter. Acadian Asset Management LLC boosted its position in Enanta Pharmaceuticals by 2.1% during the first quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company's stock valued at $4,782,000 after acquiring an additional 17,613 shares during the last quarter. Millennium Management LLC lifted its stake in Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company's stock valued at $7,435,000 after buying an additional 449,945 shares during the period. AQR Capital Management LLC boosted its stake in Enanta Pharmaceuticals by 674.7% during the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company's stock worth $1,971,000 after acquiring an additional 311,010 shares in the last quarter. Finally, PDT Partners LLC raised its stake in Enanta Pharmaceuticals by 217.5% during the 1st quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company's stock worth $586,000 after buying an additional 72,751 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Up 0.5%

NASDAQ ENTA traded up $0.04 on Friday, reaching $7.54. 20,233 shares of the stock traded hands, compared to its average volume of 282,203. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.24. The company has a market cap of $161.10 million, a price-to-earnings ratio of -1.66 and a beta of 0.77. The firm's fifty day simple moving average is $6.31 and its 200 day simple moving average is $6.05.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). The firm had revenue of $14.93 million during the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 149.57% and a negative return on equity of 79.83%. As a group, equities research analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.